Abstract

BackgroundLeflunomide is a disease modifying drug (DMARD) used in the treatment of juvenile idiopathic arthritis (JIA). Chronic uveitis is a frequent complication of JIA. Methotrexate and other DMARDS have successfully...

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
Retrospective analysis of children with uveitis treated with infliximab
Ilknur Tugal-Tutkun ... Nur Kir
Journal of American Association for Pediatric Ophthalmology and Strabismus | VOL. 12
Ilknur Tugal-Tutkun, et. al.Ilknur Tugal-Tutkun ... Nur Kir
19 Oct 2008
Leflunomide is associated with a higher flare rate compared to methotrexate in the treatment of chronic uveitis in juvenile idiopathic arthritis
J Bichler ... B Hügle
Scandinavian Journal of Rheumatology | VOL. 44
J Bichler, et. al.J Bichler ... B Hügle
20 May 2015
Timing of uveitis onset in oligoarticular juvenile idiopathic arthritis (JIA) is the main predictor of severe course uveitis
Maria E Zannin ... Donato Rigante
Acta Ophthalmologica | VOL. 90
Maria E Zannin, et. al.Maria E Zannin ... Donato Rigante
30 Jan 2012
6298 Uveitis screening in Juvenile Idiopathic Arthritis: Are we following the guidelines?
Junaid Ahmad ... Deborah Olusanya
Archives of Disease in Childhood | VOL. 109
Junaid Ahmad, et. al.Junaid Ahmad ... Deborah Olusanya
30 Jul 2024
View more papers

More From: Annals of the Rheumatic Diseases

Paper Title
Journal
Date
Author
Expert consensus recommendations for the diagnosis and treatment of chronic non-bacterial osteitis (CNO) in adults
Elizabeth M Winter ... Anne T Leerling
Annals of the Rheumatic Diseases | VOL. -
Elizabeth M Winter, et. al.Elizabeth M Winter ... Anne T Leerling
28 Nov 2024
Ivarmacitinib, a selective Janus kinase 1 inhibitor, in patients with moderate-to-severe active rheumatoid arthritis and inadequate response to conventional synthetic DMARDs: results from a phase III randomised clinical trial
Jinjing Liu ... Xiaofeng Zeng
Annals of the Rheumatic Diseases | VOL. -
Jinjing Liu, et. al.Jinjing Liu ... Xiaofeng Zeng
27 Nov 2024
CD-19 CAR-T cells for polyrefractory rheumatoid arthritis
Merav Lidar ... Abraham Avigdor
Annals of the Rheumatic Diseases | VOL. -
Merav Lidar, et. al.Merav Lidar ... Abraham Avigdor
27 Nov 2024
Correction: Olokizumab plus methotrexate: safety and efficacy over 106 weeks of treatment
-
Annals of the Rheumatic Diseases | VOL. -
--
27 Nov 2024
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.